Leo Pharma elaborates on 2030 strategy after new capital injection

Backed by Nordic Capital, Leo Pharma is now free to power ahead with the strategy that will ideally lead to Leo Pharma becoming a global, leading player in medical dermatology by 2030, according to CEO Catherine Mazzacco.

Photo: Leo Pharma / PR

The reason why Leo Pharma is gaining new capital through divesting parts of its ownership is very specific.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs